The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls
Abstract
Purpose: CHEK2*1100delC heterozygosity may be associated with an increased risk of breast cancer; however, it is unclear whether the evidence is sufficient to recommend genotyping in clinical practice. Patients and Methods: We identified studies on CHEK2*1100delC heterozygosity and the risk of unselected, early-onset, and familial breast cancer through comprehensive, computer-based searches of PubMed, EMBASE, and Web of Science. Aggregated risk estimates were compared with previous estimates for BRCA1 and BRCA2 mutation heterozygotes. Results: By using fixed-effect models for CHEK2*1100delC heterozygotes versus noncarriers, we found aggregated odds ratios of 2.7 (95% CI, 2.1 to 3.4) for unselected breast cancer, 2.6 (95% CI, 1.3 to 5.5) for early-onset breast cancer, and 4.8 (95% CI, 3.3 to 7.2) for familial breast cancer. For familial breast cancer, this corresponds to a cumulative risk of breast cancer at age 70 years in CHEK2*1100delC heterozygotes of 37% (95% CI, 26% to 56%), which compares with similar previous estimates of 57% (95% CI, 47% to 66%) for BRCA1 mutation heterozygotes and 49% (95% CI, 40% to 57%) for BRCA2 mutation heterozygotes. Conclusion: These meta-analyses emphasize that CHEK2*1100delC is an important breast cancer–predisposing gene, which increases the risk three- to five-fold. Because the cumulative risk of breast cancer at age 70 years among familial patient cases for CHEK2*1100delC heterozygotes is almost as high as that for BRCA1 and BRCA2 mutation heterozygotes, genotyping for CHEK2*1100delC should be considered together with BRCA1 and BRCA2 mutation screening in women with a family history of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802 · cited 6×
“We also compared these results with a recent metaanalysis on the risk of breast cancer for women with mutations in BRCA1 or BRCA2.”
MethodResultInfluentialChk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104 · cited 4×
“The meta-analyses emphasizes that CHEK2*1100delC heterozygosity increases the risk of breast cancer three- to five-fold, which supports previous individual studies conducted in patients with unselected, early-onset, and familial breast cancer.(3-18) The studies used for the present meta-analyses showed no evidence of…”
BackgroundResultInfluentialHeterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
CHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 551
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
Vahteristo, P., Bartkova, J., Eerola, H., Syrjäkoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomäki, K., Heikkilä, P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341943 · Cited by 467
Meijers-Heijboer, H., Wasielewski, M., Wagner, A., Hollestelle, A., Elstrodt, F., van den Bos, R., de Snoo, A., Tjon A Fat, G., Brekelmans, C., Jagmohan, S., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375121 · Cited by 227
The CHEK2 gene and inherited breast cancer susceptibility
Nevanlinna, H., & Bartek, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209877 · Cited by 219
Cited by
Breast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
RetractedMalkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Genetic Susceptibility to Cancer: The Role of Polymorphisms in Candidate Genes
Dong, L. M., Potter, J. D., White, E., Ulrich, C. M., Cardon, L. R., & Peters, U. (2008) · JAMA · doi:10.1001/jama.299.20.2423 · Cited by 461
Tung, N., Battelli, C., Allen, B., Kaldate, R., Bhatnagar, S., Bowles, K., Timms, K., Garber, J. E., Herold, C., Ellisen, L., et al. (2015) · Cancer · doi:10.1002/cncr.29010 · Cited by 430
The PRACTICAL Consortium, Day, F. R., kConFab Investigators, AOCS Investigators, Scotland, G., EPIC-InterAct Consortium, Study, L. C., Ruth, K. S., Thompson, D. J., Lunetta, K. L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3412 · Cited by 402
Self-citationBuys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., Sharma, L., Saam, J., Lancaster, J., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 399
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
Hereditary Breast Cancer: The Era of New Susceptibility Genes
Apostolou, P., & Fostira, F. (2013) · BioMed Research International · doi:10.1155/2013/747318 · Cited by 351
Cybulski, C., Wokołorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., Masojć, B., Dębniak, T., Górski, B., Blecharz, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0778 · Cited by 254
Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CH EK 2 *1100delC Carriers
Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks, A., Adank, M. A., Meijers, H., Waisfisz, Q., Hollestelle, A., Schutte, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.5844 · Cited by 173
Self-citationGallagher, S., Hughes, E., Wagner, S., Tshiaba, P., Rosenthal, E., Roa, B. B., Kurian, A. W., Domchek, S. M., Garber, J., Lancaster, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8501 · Cited by 137
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden
Wendt, C., Lindblom, A., Arver, B., von Wachenfeldt, A., & Margolin, S. (2015) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-015-0036-z · Cited by 16
Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention
Kassem, N., Stout, L. A., Hunter, C., Schneider, B., & Radovich, M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00278 · Cited by 5
Metadata
- Authors
- Weischer, M., Bojesen, S. E., Ellervik, C., Tybjærg-Hansen, A., & Nordestgaard, B. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-01
- Volume
- 26
- Issue
- 4
- Pages
- 542-548
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149805321
- Cited by
- 306
- References
- 42
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.